Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alamar Biosciences filings document its transition to a Nasdaq-listed public company, its proteomics business, and its formal reporting of operating results, capital structure, and governance. Registration materials describe the company’s NULISA-based Precision Proteomics platform, product categories, single-segment structure, and common stock offering.
The company’s 8-K filings cover public-company events including quarterly financial results, completion of its initial public offering, amended and restated certificate of incorporation, amended and restated bylaws, and related exhibits. Its S-1/A registration statement documents IPO-related disclosures, risk factors, business description, securities registration, and governance information.
Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.
The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering. Several classes of preferred and Class A shares automatically converted into Class B Common Stock and were then reclassified into Common Stock immediately before the IPO, with no cash changing hands.
The filing also shows a grant of 76,509 restricted stock units that vest monthly, and a new stock option for 341,191 shares of Common Stock at an exercise price of $17.00 per share, vesting over four years. Many option entries reflect technical reclassifications between Class B Common Stock and Common Stock rather than market trades.
Alamar Biosciences Chief Financial Officer Justin J. McAnear reported new equity awards and an option restructuring. He received 37,220 shares of Common Stock as restricted stock units that vest monthly from the grant date, conditioned on his continued service.
He was also granted stock options for 163,358 shares of Common Stock at an exercise price of $17.00 per share, with 25% vesting on April 16, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continued service. In addition, 570,719 stock options with a $4.62 exercise price were reclassified so the underlying security changed from Class B Common Stock to Common Stock in connection with the company’s initial public offering, with no open-market buying or selling reported.
Alamar Biosciences director Nicholas Naclerio reported multiple equity-related transactions. An entity associated with him purchased 235,294 shares of Common Stock at $17.00 per share, increasing indirect ownership. He also received 5,686 restricted stock units that vest in three equal installments on April 20, 2027, April 20, 2028 and April 20, 2029, contingent on continued service.
In addition, he was granted a stock option for 25,599 shares at an exercise price of $17.00 per share, vesting from April 16, 2027 through April 16, 2029 and expiring on April 15, 2036. Several series of Preferred Stock and a convertible promissory note held by Illumina Innovation Fund entities automatically converted into Class B Common Stock, which was then reclassified into Common Stock in connection with the company’s IPO, with Naclerio disclaiming beneficial ownership except for his pecuniary interests.
Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.
Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.
Alamar Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 (Registration No. 333-294697) to replace Exhibit 5.1. The amendment is limited to Item 16(a) and Exhibit updates and states the registration statement shall become effective upon filing in accordance with Rule 462(d).